Hutchison Chi-Med begins phase 1 study of 'HMPL-306'
24th Jul 2020 15:45
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.
Read moreHutchison Chi-Med gets FDA fast track approval for fruquintinib
18th Jun 2020 09:18
(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the development of 'fruquintinib'.
Read moreHutchison Chi-Med venture to surrender unused land in Guangzhou
9th Jun 2020 14:06
(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings - has agreed the planned return of its remaining 34 years land-use rights on its 30,000 square metre unused site in Tong He Town with the Guangzhou government.
Read moreHutchison Chi-Med shares up on updated results from 'CALYPSO'
10th Feb 2020 07:36
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.
Read moreHutchison Chi-Med upbeat on progress with surufatinib
20th Jan 2020 16:00
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.
Read moreHutchison Chi-Med gets priority review for 'surufatinib' in China
20th Dec 2019 15:48
(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.
Read moreHutchison China Meditech expands collaboration with Innovent
10th Oct 2019 15:45
(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..
Read moreHutchison Chi-Med initiates latest study of HMPL-523
4th Oct 2019 15:21
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.
Read moreHutchison China MediTech launches trial for autoimmune disorder treatment
23rd Aug 2019 11:25
(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.
Read moreHutchison Chi-Med makes progress with surufatinib
14th Jun 2019 14:40
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.
Read moreHutchison loss widens as China legislation hampers revenue
11th Mar 2019 11:54
(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.
Read moreHutchison Chi-Med enters four new drug test collaborations
29th Nov 2018 12:17
(Sharecast News) - Hutchison China MediTech, doing business as Chi-Med, has entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of its 'surufatinib' (HMPL-012 or sulfatinib) and 'fruquintinib' products, in combination with checkpoint inhibitors.
Read moreHutchison China MediTech presents promising data in Washington
14th Nov 2016 11:11
(ShareCast News) - Hutchison China MediTech presented data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokinetics and pharmacodynamics of single and multiple doses of HMPL-523 on Monday, to the Annual Meeting of the American College of Rheumatol
Read moreHutchison China's JV receives $60m land compensation
31st Oct 2016 10:05
(ShareCast News) - Hutchison China MediTech's prescription drug joint-venture received $59.5m on Friday from the Shanghai government under its land compensation agreement. The joint-venture with a subsidiary of Shanghai Pharmaceuticals, Shanghai Hutchison Pharmaceuticals, entered into a compensation
Read moreDirector dealings: Chi-Med director's wife bags a bargain?
9th Aug 2016 15:41
(ShareCast News) - The wife of Hutchison China MediTech (Chi-Med) director Christopher Nash has swooped into the market to pick up a few of the company's shares a after hearing good reports on the China-based biopharma outfit's recent interim results and bulging drug pipeline. Mrs Nash, wife of the
Read more